Myriad cancer testing franchise to lose share, says Leerink Leerink says Horizon Blue Cross Blue Shield's announcement that it is terminating its participation agreements with Myriad Genetics is consistent with its view that the company's core hereditary cancer testing franchise will experience market share and price erosion over time. Leerink notes defenders of Myriad had argued that the company remained in Horizon's network while LabCorp (LH) was the preferred provider, which will no longer be the case. It has a Market Perform rating on Myriad.
LabCorp: Covance announces agreement with leading pharmaceutical company Laboratory Corporation of America Holdings announced that Covance Drug Development has received a multi-year award from a leading pharmaceutical company to use Covance's Xcellerate platform as an exclusive central monitoring solution for their worldwide clinical trials portfolio. This landmark agreement with a top-tier pharmaceutical company for Covance's first-in-kind Software-as-a-Service offering reflects the company's unique technology capabilities, and reinforces its position as an industry innovator and leader in clinical informatics solutions.